Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost

This article was originally published in The Pink Sheet Daily

Executive Summary

European Society of Cardiology Congress abstract for small study suggests Roche's dalcetrapib is safe and works on plaque burden.

You may also be interested in...



Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation

Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.

Simcere Teams Up Again With Bristol-Myers For Co-Development In China

After signing a deal in deal in November 2010 for a MET-VEGFR-2 inhibitor, Simcere and BMS switch gears for a CETP inhibitor.

Simcere Teams Up Again With Bristol-Myers For Co-Development In China

After signing a deal in deal in November 2010 for a MET-VEGFR-2 inhibitor, Simcere and BMS switch gears for a CETP inhibitor.

Related Content

Topics

UsernamePublicRestriction

Register

PS072681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel